cl 387785 has been researched along with Carcinoma, Non-Small Cell Lung in 5 studies
CL 387785: structure in first source
N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y | 1 |
| Sheng, Z | 1 |
| Dong, Z | 1 |
| Wang, J | 1 |
| Yano, S | 1 |
| Nakagawa, T | 1 |
| Zannetti, A | 1 |
| Iommelli, F | 1 |
| Speranza, A | 1 |
| Salvatore, M | 1 |
| Del Vecchio, S | 1 |
| Desai, AA | 1 |
| Ratain, MJ | 1 |
| Kobayashi, S | 1 |
| Shimamura, T | 1 |
| Monti, S | 1 |
| Steidl, U | 1 |
| Hetherington, CJ | 1 |
| Lowell, AM | 1 |
| Golub, T | 1 |
| Meyerson, M | 1 |
| Tenen, DG | 1 |
| Shapiro, GI | 1 |
| Halmos, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An EGFR-TKIs Benefit Non-small Cell Lung Carcinoma Patients Identification Strategy and Treatment Response Using Molecular Imaging[NCT02717221] | 100 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for cl 387785 and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug R | 2023 |
The current state of molecularly targeted drugs targeting HGF/Met.
Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non | 2014 |
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carc | 2012 |
EGFR pharmacogenomics: the story continues to mutate and evolve.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Huma | 2005 |
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell L | 2006 |